The place is DeepMind’s AI protein design spinout? The Alphabet-owned AI firm took the biology world by storm in 2020 with AlphaFold2, the protein construction prediction AI platform that “solved” a decades-old biology downside. In 2021, the corporate spun out Isomorphic Labs, an AI drug discovery firm. However Isomorphic’s preliminary focus is on small-molecule drug discovery, with protein-based medicine remaining a distant twinkle within the firm’s eye.
Watching the Isomorphic spinout was irritating for Simon Kohl. He was a part of the Nobel Prize-winning crew that developed Alphafold2, and afterward labored on DeepMind’s protein design crew for 2 years. Isomorphic has a broad imaginative and prescient and goes after many issues directly, he instructed STAT, and he felt a “laser-focused entity” centered on protein design would do a greater job.
“I cherished working at DeepMind. It’s such a incredible place and I actually loved the time on the AlphaFold crew, however actually did really feel to maximise influence in [protein design]it required its personal entity,” mentioned Kohl.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
View All Plans
